Answers are grounded in this paper and cite their sources.
I am writing this commentary to caution surgeons not to overinterpret the results mentioned in the original Reeds et al1 study (of which I was an author, and which was referenced in the Letter to the Editor from Drs Hasengschwandtner and Gundermann) and assume that the results offer proof that injection lipolysis using drugs from compounding pharmacies is safe and efficacious. The purpose of my response is not to rebut the comments from Hasengschwandtner and Gundermann. The original article by Reeds et al1 was an institutional review board–approved study in a very small group of subjects utilizing a combination of phosphatidylcholine/deoxycholate (PC/DC) produced by MasterPharm (Richmond Hill, New York), a compounding pharmacy. This PC/DC formulation represents only 1 potential combination of PC/DC and, as there is no established or proven ideal combination, other compounding pharmacies might produce a different formulation. The best agent would be a synthetic single drug of known purity and concentration that has gone through the US Food and Drug Administration (FDA) drug approval process to establish safety and efficacy as well as proper dosing and delivery parameters. Currently, neither of the drugs nor the drug combination used in the Reeds et al1 study is FDA approved for subcutaneous injection for any purpose. This is relevant for several reasons. First, because it is not yet FDA approved, the formulation has not gone through the agency's stringent evaluation for safety and efficacy. The fact that we did not experience serious adverse events in this small series should not be construed as proof that these treatments or drug combinations are safe. Furthermore, the FDA is currently on heightened alert regarding compounded drugs because of the fungal meningitis outbreak2; the US Senate Committee on Health, Education, Labor and Pensions and the US House Committee on Energy and Commerce are both proposing legislation to improve the safety of compounded drugs. This means that attorneys will also be on the lookout for any complaints or complications resulting from adverse events with these treatments. Second, if you choose to use an unapproved product outside of an approved study, you need to be sure your liability insurance carrier will cover you in case a claim should occur. Dr Young is a consultant for Lithera (San Diego, California), Neodyne Biosciences (Menlo Park, California), and RXi Pharmaceuticals (Worcester, Massachusetts). He serves as principal investigator (PI) or co-PI in clinical trials funded by AirXpanders (Palo Alto, California), Allergan (Irvine, California), Cohera Medical (Pittsburgh, Pennsylvania), Excaliard Pharmaceuticals (Carlsbad, California), Kythera Biopharmaceuticals (Calabasas, California), and RXi Pharmaceuticals. Dr Young serves on the scientific advisory boards of Allergan, GlaxoSmithKline (Middlesex, UK), and RXi Pharmaceuticals. He is both an author and the editor of Plastic Surgery Pulse for Quality Medical Publishing (St Louis, Missouri).
No takes yet. Share an insight, caveat, or question.
V. Leroy Young (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: